GC녹십자웰빙's RZL-012 Meets Primary Endpoints in Chinese Phase 3 Trial
GC녹십자웰빙 announced that its exclusive drug candidate RZL-012 achieved primary efficacy and safety endpoints in a pivotal Phase 3 trial in China involving 480 adults with submental fat.